The Global Initiative for Asthma (GINA) recommends the corticosteroid, azithromycin, anti-IL4R, anti-thymic stromal lymphopoietin, long-acting muscarine anticholinergic, short-acting β-agonists, and anti-IgE antibody omalizumab for the treatment of severe asthma [31]. The gene discussed is TSLP; the disease is asthma.